In this episode of The Issue, CEO of Life Biosciences Jerry McLaughlin joins hosts Sanjay D’Souza, PhD and Jason West, PhD for a discussion on how epigenetic reprogramming could restore function in aging and injured cells. He explains the science behind ER-100, an investigational gene therapy now in a Phase 1 trial for optic neuropathies, and explores the broader promise of targeting age-related diseases to help improve quality of life.

Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/